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Abstract
In this study, we analyzed patterns of combined benzodiazepines and alcohol use among the Spanish general population over the age of
16 years. The study was based on information from the 1997 Spanish National Household Health Survey. A total of 6,396 persons over 16 years
of age, a representative sample of noninstitutionalized Spaniards, were surveyed. One percent of the population are consumers of
benzodiazepines and daily drinkers of alcohol; fundamentally, these consumers are men, of whom 15.4% drink alcohol at a high level
( > 50 units/week). Findings show the frequency of concurrent use of benzodiazepines and alcohol by the Spanish population. D 2002 Elsevier
Science Inc. All rights reserved.
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1. Introduction
Benzodiazepines are widely prescribed because of both
their effectiveness and their safety in the treatment of multiple
psychiatric and physical diseases. But, despite their being
safe drugs, one of the greatest risks is that adverse effects may
be produced when taking benzodiazepines owing to their
interaction with other substances—particularly with psycho-
active medication and alcohol. Adverse drug interactions are
an important clinical problem, and it is well known that
several different mechanisms are implicated in their patho-
genesis. In regard to benzodiazepines, alcohol interferes both
at the pharmacokinetic and at the pharmacodynamic level,
which means that the occurrence of adverse effects is more
frequent (Harris et al., 1998; Tanaka & Misawa, 1998).
Benzodiazepines are widely taken in Spain, more com-
monly by women and the elderly (Del Rı´o & Alvarez, 1996;
Rayo´n et al., 1996). Additionally, the taking of hypnotic and
anxiolytic benzodiazepines has increased considerably in
the past 10 years, compared with the decrease in consump-
tion in other Western countries, such as the Nordic coun-
tries, the United Kingdom, and the United States (Rayo´n
et al., 1996; Tiller, 1994). Moreover, in Spain, drinking
alcohol is a social habit, and there are many who drink
regularly (Del Rı´o et al., 1995).
Information relating to the use of benzodiazepines and
alcohol together is scant, and the aim of this study was to
analyze patterns of combined benzodiazepines and alcohol
use among the Spaniards.
2. Methods
The study was based on information from the 1997
Spanish National Household Health Survey, undertaken by
the Ministry of Health and Consumption (Ministerio de
Sanidad y Consumo, 2000) to obtain data on aspects relating
to health and the use of health resources. The procedures
followed were in accordance with the ethical standards of
the committee responsible for human experimentation (the
Ethics Committee of the Faculty of Medicine) and with the
Helsinki Declaration of 1975, as revised in 1983.
A survey of 6,396 persons over 16 years of age, a
representative sample of noninstitutionalized Spaniards,
was carried out. The sample was stratified: first, by Spanish
communities; second, in seven stages, by number of inhab-
itants; third, by cities in each of the communities; and,
finally, by sex (3,102 males, 3,294 females) and age (in
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years) (1,353, age 16–25; 1,227, age 26–35; 1,012, age
36–45; 853, age 46–55; 927, age 56–65; 673, age 66–75;
352, age >75).
Those surveyed were asked whether they had taken
benzodiazepines in the 2-week period before the interview.
In regard to alcohol, they were asked whether they had had
any type of alcoholic beverage in the preceding 2 weeks
and, if the answer was affirmative, how often, the number of
alcoholic drinks consumed on each occasion, and the type
(wine, beer, or spirits). Daily drinkers were considered to be
those who spoke of having at least one drink a day. The
amount of alcohol consumed was expressed in grams of
absolute alcohol consumed per day, in accordance with the
alcohol content of Spanish drinks and the volume of intake
of each of the different drinks.
To facilitate the registration and monitoring of alcohol
consumption and to provide comparable data, the use of a
drink-unit system is recommended. A unit is the alcohol
content in defined volumes of different beverages with a
standard strength (the standard drink unit for Spain has been
defined as 10 grams of pure alcohol) (Rodriguez-Martos
et al., 1999). Drinkers were classified according to their
consumption level: low consumption (men, 21 units/week,
and women, 14 units/week); moderate consumption (men,
22–50 units/week, and women, 15-35 units/week); high
consumption (men, >50 units/week, and women, >35 units/
week) (Del Rı´o et al., 1995). The questionnaires were
administered by trained interviewers.
Statistical analysis was undertaken with the use of SAS
software version 6.07. Frequencies were compared by
utilizing c2 analysis. Values of P less than or equal to .05
were considered to be significant differences.
3. Results
Of the participating adult population, 6.4% (males, 4.1%;
females, 8.5%; c2 = 50.86, df = 1; P < .0001) had taken
benzodiazepines in the 2 weeks before the survey, and use
increased with increasing age: from 1.4% in the group
16-to-25 years of age to 15.9% in the group older than
75 years of age (Fig. 1). In addition, 23.7% (males, 33%;
females, 10.9%; c2 = 613.99, df = 1; P < .0001) of the
population drank alcohol on a daily basis.
When use of benzodiazepines and consumption of alco-
hol were analyzed jointly, 16% were seen to be daily
drinkers (1% of all those surveyed), more commonly among
men (30.5%) than among women (9.3%; c2 = 29.25, df = 1;
P < .0001) (Table 1). Consumption increased with increas-
ing age of the population, from 0% in the 16-to-25 years
age group to 12.1% in the 26–35 years age group to a
maximum of 23% in the 56-to-65 years age group, after
which it went down (Fig. 1). Mean alcohol consumption
among those taking benzodiazepines and drinking daily was
35.99 ± 28.67 g/day: 44.28 ± 44.22 g/day for men and
17.65 ± 9.19 g/day for women. In terms of benzodiazepine
use and daily alcohol consumption, 58.5% drank at a low
level, 32.3% drank at a moderate level, and 9.2% drank at a
high level. Differences according to sex also were evident
(c2 = 9.98, df = 2, P < .01); women drank alcohol at a low
level (80.8%) more often than men (43.6%), whereas men
consumed alcohol at moderate (41.0%) and high (15.4%)
levels more frequently than women (19.2% and 0%,
respectively) (Table 1).
There were more daily consumers of alcohol (24.2%)
among those not taking benzodiazepines than among those
taking them (16%, c2 = 14.31, df = 1, P < .0001).
Nevertheless, the distribution of drinkers according to their
level of consumption did not differ, either among those who
took benzodiazepines or those who did not take them
(c2 = 1.73, df = 2, P > .05).
4. Discussion
According to our study results, 6.4% of the Spanish
population take benzodiazepines, especially females andFig. 1. Alcohol consumption among those taking benzodiazepines.
Table 1
The use of benzodiazepines and alcohol among the Spanish population
Total sample
Total
(n = 6396) %
Males
(n = 3102) %
Females
(n = 3294) %
Take benzodiazepines 6.4 4.1 8.5
Drink daily 23.7 33.0 10.9
Take benzodiazepines +
drink daily
1.0 1.3 0.8
Population taking benzodiazepines
Total
(n = 407) %
Males
(n = 127) %
Females
(n = 280) %
Daily drinkers 16 30.5 9.3
Consumption level
Low 58.5 43.6 80.8
Moderate 32.3 41.0 19.2
High 9.2 15.4 0
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the elderly. In addition, 1% of the population are consumers
of benzodiazepines and daily drinkers of alcohol; fun-
damentally, they are men, of whom 15.4% drink alcohol at
a high level (>50 units/week). Our findings also indicate that
alcohol consumption is more common among people not
taking benzodiazepines than among those who do take them.
In our study, we observed a lower rate of benzodiazepine
use than that in other, nearby countries, such as Finland
(Joukamaa et al., 1995), Italy (Magrini et al., 1996), and the
Netherlands (van der Waals et al., 1993; van Hulten et al.,
1998), but a clearly higher rate than that of the United
Kingdom (Ohayon et al., 1998) and the United States
(Simon et al., 1996), although differences among different
types of populations have to be taken into consideration.
With regard to alcohol consumption among those who take
benzodiazepines, 15.4% consume alcohol at a high level. In
other studies, a high rate of alcohol dependence was found
among those who take high doses of benzodiazepines
(Lekka et al., 1997).
In the present study, benzodiazepines were more fre-
quently used by women than by men, as previously reported
(Magrini et al., 1996; Rayo´n et al., 1996; van Hulten et al.,
1998). In addition, benzodiazepine use together with alcohol
consumption were analyzed. Men took benzodiazepines
with alcohol more frequently than did women, as observed
in previous studies, which correlates with the fact that
alcohol consumption is more common among men than
women (Del Rı´o et al., 1995).
Pharmacokinetic and pharmacodynamic interactions
between alcohol and benzodiazepines can have significant
clinical implications, such as the impairment of many motor,
sensory, and neurological functions, with a greater risk of
sedation and, consequently, a greater risk of accidents,
including road, work, and possible sudden death (Barbone
et al., 1998; Neutel, 1998; Tanaka & Misawa, 1998). These
side effects can impair the quality of life and have led to a
critical discussion about the practice of prescribing benzo-
diazepines and the information provided by physicians
(Gutierrez-Lobos et al., 2001). Our findings do not permit
us to establish whether interactions take place between
benzodiazepines and alcohol but allow us to presume that
they did in some cases. To prevent drug–ethanol interac-
tions, physicians should pay more attention to this possible
occurrence (Del Rı´o et al., 1996).
European Union regulations (Directive 92/27/CEE) and
Spanish legislation (Royal Decree 2.236/93, December 17)
establish norms for labeling and package inserts for medi-
cines used by human beings and define the sections to be
included. Section 4.5 refers specifically to the interactions
with other drugs, including alcohol. Therefore, the package
inserts and Summary of Product Characteristics must pro-
vide information on the possible side effects of these
substances as well as their possible interactions with others,
including alcohol. In Spain, warning is given for all benzo-
diazepines in regard to their interactions with alcohol. But,
apart from this information in the package inserts, it is very
important for a physician prescribing a benzodiazepine to
ask the patient about his or her habits relating to alcohol
consumption and to inform and warn the patient of the
possible risks when taking the benzodiazepine together
with alcohol.
In accordance with the Spanish regulation, benzodiaze-
pines must be prescribed by a physician, but there is no
specific regulation for benzodiazepine prescription. A
stricter and specific regulation regarding benzodiazepine
prescription has been introduced in other countries (Wein-
traub et al., 1991), with a view to encouraging more rational
prescription of these drugs.
The beneficial effects of benzodiazepine treatment for
certain disorders (anxiety disorder, panic disorder, sleep
disorder) have been clearly shown. Any benzodiazepine
prescription should be preceded by careful diagnostic evalu-
ation and consideration of the potential risks and benefits of
alternative treatment options, mainly if there is a history of
alcohol or other drug abuse (Posternak & Mueller, 2001).
Thus, appropriate education is necessary for both the patient
and the physician, perhaps formalized in practice guidelines,
instead of specific regulations that can restrict clinical judg-
ment and lead to less desirable alternatives (Glass, 1991).
Nevertheless, it is essential to research prescription
patterns and how benzodiazepines are taken in Spain to
provide guidelines for regulatory decisions, with a view to
implementing a more appropriate and rational use of
such drugs in the future (Del Rı´o & Alvarez, 1996; Rayo´n
et al., 1996).
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